S Bank Fund Management Ltd Sells 11,977 Shares of Royalty Pharma PLC $RPRX

S Bank Fund Management Ltd lowered its stake in Royalty Pharma PLC (NASDAQ:RPRX) by 27.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 30,972 shares of the biopharmaceutical company’s stock after selling 11,977 shares during the quarter. S Bank Fund Management Ltd’s holdings in Royalty Pharma were worth $1,197,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. Strs Ohio raised its stake in Royalty Pharma by 2.8% during the 4th quarter. Strs Ohio now owns 9,318 shares of the biopharmaceutical company’s stock valued at $360,000 after buying an additional 252 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd boosted its stake in shares of Royalty Pharma by 0.6% in the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 43,287 shares of the biopharmaceutical company’s stock worth $1,673,000 after buying an additional 255 shares during the last quarter. CWM LLC grew its holdings in shares of Royalty Pharma by 1.5% in the third quarter. CWM LLC now owns 18,591 shares of the biopharmaceutical company’s stock worth $656,000 after acquiring an additional 281 shares during the period. Private Trust Co. NA increased its position in Royalty Pharma by 52.9% during the fourth quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 288 shares during the last quarter. Finally, Hudson Bay Capital Management LP increased its position in Royalty Pharma by 1.0% during the third quarter. Hudson Bay Capital Management LP now owns 29,384 shares of the biopharmaceutical company’s stock valued at $1,037,000 after acquiring an additional 289 shares during the last quarter. Institutional investors own 54.35% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on RPRX shares. UBS Group raised their target price on Royalty Pharma from $51.00 to $57.00 and gave the stock a “buy” rating in a research report on Tuesday, April 21st. Weiss Ratings raised shares of Royalty Pharma from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday. Morgan Stanley increased their price objective on shares of Royalty Pharma from $61.00 to $63.00 and gave the stock an “overweight” rating in a research note on Friday, April 10th. TD Cowen reissued a “buy” rating on shares of Royalty Pharma in a report on Friday, February 27th. Finally, Citigroup upped their target price on shares of Royalty Pharma from $48.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, January 27th. Six research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Royalty Pharma presently has an average rating of “Buy” and a consensus price target of $50.33.

Royalty Pharma Stock Up 0.5%

Shares of RPRX stock opened at $50.44 on Wednesday. The company has a market capitalization of $29.10 billion, a price-to-earnings ratio of 37.36, a PEG ratio of 3.21 and a beta of 0.40. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.40 and a quick ratio of 2.40. The company’s fifty day moving average price is $47.42 and its 200-day moving average price is $42.56. Royalty Pharma PLC has a one year low of $31.97 and a one year high of $50.82.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings results on Wednesday, February 11th. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.33 by $0.13. The business had revenue of $621.99 million during the quarter, compared to analyst estimates of $839.97 million. Royalty Pharma had a return on equity of 28.21% and a net margin of 32.38%. Sell-side analysts expect that Royalty Pharma PLC will post 5.08 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be given a dividend of $0.235 per share. The ex-dividend date is Friday, May 15th. This represents a $0.94 annualized dividend and a dividend yield of 1.9%. Royalty Pharma’s dividend payout ratio (DPR) is currently 69.63%.

Insider Transactions at Royalty Pharma

In related news, CFO Terrance P. Coyne sold 34,791 shares of the business’s stock in a transaction that occurred on Tuesday, April 28th. The stock was sold at an average price of $49.78, for a total value of $1,731,895.98. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 139,164 shares of company stock worth $6,624,902. 18.84% of the stock is currently owned by company insiders.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.